Lung Metastases, Cytoreductive Nephrectomy and Favourable Risk Group Associated with a Higher Probability of Response to First-Line Combination Therapy in mRCC
Findings from the international metastatic renal cell database consortium
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Granting a Marketing Authorisation for Stimufend
Stimufend is a biosimilar, highly similar to the reference product Neulasta (pegfilgrastim), which was authorised in the EU in 2002
Adding Darolutamide to ADT and Docetaxel Prolongs Overall Survival in Patients with Metastatic, Hormone-Sensitive Prostate Cancer
Improvements also observed with respect to key secondary endpoints, with no increase in adverse events
Higher Risk of Major Adverse Cardiovascular Events and Cancers with Tofacitinib
EMA starts safety review of Janus kinase inhibitors used for inflammatory disorders
Cancer Mortality Predictions for the 10 Major Causes of Cancer Mortality and Total Cancer in 2022 in the European Union
Additional declines in cancer mortality rates predicted for 2022
In NeoTRIP, Atezolizumab with Neoadjuvant Carboplatin/Nab-Paclitaxel was Feasible in TNBC, but Led to Non-Significant pCR Increase
The study primary endpoint is event-free survival, and lack of improvement in pathologic complete response may be misleading as to the impact of atezolizumab on long-term efficacy in high-risk triple-negative breast cancer
Late Breast Cancer Recurrence Less Aggressive and Associated with Better Prognosis Compared to Early Recurrence
Findings from the Danish Breast Cancer Group
Pemigatinib, a Selective FGFR 1–3 Inhibitor Is Safe, Tolerable and Demonstrates Pharmacologic, Clinical Activity
Final results from the FIGHT-101 study
Older Patients with Cancer and High-Risk Geriatric Profiles at Greater Risk for Death and Other Adverse Sequelae of COVID-19
Findings from the COVID-19 and Cancer Consortium cohort study
Frontline Treatment with Brentuximab Vedotin Plus CHP Provides Clinically Meaningful Improvement in Survival Compared to CHOP in Patients with PTCL
5-year update from the ECHELON-2 study in patients with peripheral T-cell lymphoma
EMA Recommends Extension of Therapeutic Indications for Avapritinib
It adopted two new strengths and a new indication for the treatment of advanced systemic mastocytosis
Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After First-Line Platinum-Containing Chemotherapy
Findings from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study